Though far less effective than other LSD1 inhibitors as a cytotoxic agent (100), TCP was previously demonstrated to sensitize both APL and non-APL AML cells to differentiation-inducing ATRA treatment (106). The gene discussed is KDM1A; the disease is acute promyelocytic leukemia.